InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens

InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.

Original reporting
Published Nov 13, 2026, 5:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 5:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens — source image
Decision brief

The 30-second read

$NSPRBearishLow
01

Why it matters

The earnings miss and cash depletion may pressure the stock, but the FDA nod and upcoming equity raise could mitigate downside.

02

Market read

Micro‑cap biotech earnings with FDA approval; likely short‑term negative sentiment but long‑term upside potential.

03

What to watch

Cash runway of $19.2M and potential $10M from warrant exercises may support near‑term liquidity.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

InspireMD discussed its Q3 2026 results, FDA approval of CGuard Prime for TCAR, and an underwritten equity offering.

Company-level read

Ticker impact

$NSPRBearishHigh confidence
Context

Q3 2026 earnings call disclosed revenue down 11% YoY to $2.2M, net loss of $9.8M and cash of $19.2M, plus FDA approval of CGuard Prime.

Expected impact

likely downside as market prices in the revenue decline and loss

Evidence & confidence

The disclosed financials are materially worse than prior period and no guidance was provided, creating uncertainty for investors.

Market effects

Signals potential headwinds for the vascular device sector as FDA approvals may not translate into immediate sales.

Limited to US biotech investors; no broader regional effect.

Minimal global impact; primarily a micro‑cap specific event.

Counterpoint

The FDA approval could unlock a sizable US market opportunity, offering upside if execution succeeds.

Key entities

  • InspireMD Inc

    Medical device maker focused on vascular implants.

  • Marvin Slosman

    CEO of InspireMD.

Related articles

$NSPRHighAI 8/10

InspireMD (NSPR) Q3 2026 Earnings Call Transcript

InspireMD (NSPR) announced FDA approval for its CGuard Prime TransCarotid Stent System, expanding U.S. market access by 40,000 annual procedures. Q3 2026 international revenue grew 9% YoY to $2.2M. The company plans commercial execution and cost alignment, with a 20% workforce reduction. FDA submission for the CGuard Prime 135 CAS delivery system is expected by year-end.

$NSPRHigh

InspireMD Reports Third Quarter 2026 Financial Results

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call to

$NSPRHighAI 8/10

InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard ® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR

$NSPRMed

InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate

InspireMD (NSPR) reported Q2 2026 revenue of $1.77M, missing estimates of $2.54M, and a net loss of $0.17 per share, beating expectations. Shares fell 7.06% due to revenue shortfall and U.S. recall impacts. The company expects FDA decisions on key products later in 2026. International revenue rose 21% YoY, while U.S. revenue was negative due to recall-related credits.